ISSUE 1: TOP 20 MOST INNOVATIVE HEALTHCARE TECHNOLOGY COMPANIES IN 2019

Anne Wojcicki, Co-Founder & CEO

23andMe

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits.Our mission is to help people access, understand and benefit from the human genome.

Peter Hickey, CEO

Peter Hickey, CEO

Adaptiiv Medical Technologies

A 67-year-old female was treated at the Nova Scotia Health Authority for mycosis fungoides of the forehead, eyelid, and nose with mycosis fungoides involving the upper face. As a part of her treatment plan, the application of bolus for Modulated Electron Radiation Therapy (MERT) was necessary to deliver the prescribed dose to the skin surface to treat her disease with two separate electron fields.

Matthew Stoudt, CEO

AppliedVR

AppliedVR is the leader in therapeutic virtual reality, transforming healthcare through the power of pixels. Since its founding in 2015, appliedVR has delivered scientifically designed and validated digital health solutions to over 20,000 patients in more than 250 hospitals and in 8 countries globally. The company’s leading digital wellness platform has been used to impact chronic pain as well as acute pain and anxiety experiences before, after, and during surgery, child labor, oncology infusions, emergency room procedures, and rehabilitation sessions.

Dr. Abraham Heifets CEO

Atomwise

Atomwise patented the first deep learning technology for structure-based small molecule drug discovery. This AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve. We’ve partnered with some of the world’s largest pharmaceutical and agrochemical companies, and with more than 50 leading academic institutions and hospitals, to tackle the challenges of discovering and developing better drugs and chemicals. Recently, Atomwise raised $45 million from leading venture capital firms to support the development and application of its AI technology.

Joanna Shields, CEO

BenevolentAI

BenevolentAI is the global leader in the development and application of artificial intelligence (“AI”) for scientific innovation. We aim to accelerate the journey from inventive ideas to medicines for patients by developing AI to generate new treatments for some of the world’s 8,000 untreated diseases.

Josef Scheiber, MD & Founder

BioVariance

Medical errors are as fatal as terminal diseases. Often numerous patients die due to the recurring medical errors in the healthcare systems. The modern healthcare sector is continuously challenged with this festering issue as they strive to deliver safe and higher quality care.

CAIDE Systems

CAIDE Systems

Jacob Lee, CEO

Despite the upheaval that AI has created in the healthcare space, the lack of well-annotated data has been the biggest challenge in the development of disease detection AI engines. It slows the process and is very expensive. Moreover, annotation and labeling demand a heavy workload from medical doctors in the development stage of medical AI engines. Applying his extensive experience in objective recognition for medical image-based diagnosis using AI deep learning, Jacob Lee found the perfect solution to reduce the burden from this data annotation and labeling process.

Tanveer Patel Co-Founder & CEO

Concert Care

Digitization has crawled into every phase of healthcare. As consumers of healthcare are gaining more medical knowledge, the demand for better service and outcomes is increasing like never before; and the only means to meet this need is through technology. “The best way to deliver healthcare to all at high quality is to be preventative and reach the consumers early before they need it,” notes Tanveer Patel, Co-Founder and CEO of ConcertCare.

Brendan Frey, Founder & CEO

Deep Genomics

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies.The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.

Nat Turner, Co-Founder & CEO

Flatiron Health

Flatiron Health is a healthcare technology company, develops software that connects community oncologists, academics, hospitals, life science researchers, and regulators on a shared technology platform.It offers Flatiron Platform, a web-based business and clinical intelligence data platform that integrates and structures disparate information systems to produce a view of the patient population, provides analytics for business intelligence, resource utilization, marketing, treatment patterns, network management, and research and clinical trials, and allows cancer care providers and life sciences companies to track metrics related to cancer care, monitor adherence to national guidelines across their clinicians, match patients to clinical trials in real-time, and ask custom questions of their data.

Mike Klein, CEO

Genomenon

A software solution that allows rapid, automated, and accurate analysis of next-generation sequencing data to speed up discovery work and diagnosis.

Dan Burton, CEO

Health Catalyst

Health Catalyst is dedicated to enabling health care organizations to fundamentally improve care by building the most comprehensive and fully integrated suite of healthcare data warehousing and process improvement solutions available.Health Catalyst was formed by a group of healthcare veterans with vast data warehousing and quality improvement experience. Our founders and executives collaborated for nearly a decade to revolutionize clinical process models using analytics. During development, they faced numerous hurdles in the quest to develop a data warehouse that could handle the complexities unique to healthcare data.

Jun Wang, Founder & CEO

iCarbonX

iCarbonX is a technology company that is changing how people monitor and understand their health status and optimize their lives. We are building the platform and tools for digitizing, analyzing, and understanding life, and delivering intelligent products and applications—designed for every aspect and stage of life—to help everyone make smarter choices, every day.

Joseph M. DeVivo, CEO

InTouch Health

InTouch Health provides the most reliable, dedicated cloud-based network and virtual care solutions that ensure connectivity for health systems, providers, and patients at all times. Today, InTouch Health supports more than 2,500 care locations around the world – including many of the top 20 health systems – as they deploy telehealth programs across their enterprises. InTouch Health has surpassed 2.2 million network sessions, which includes 1,000,000 telehealth virtual care sessions over the InTouch Telehealth Network.

Christopher J. Ianelli, MD, CEO

iSpecimen Inc.

During his service at the Brigham and Women’s Hospital in Boston, Dr. Christopher Ianelli noticed a software solution that orchestrated the distribution of leftover specimens to researchers developed within the clinical laboratory of the hospital. Acknowledging that these “clinical remnant” specimens held tremendous value for medical research, he quickly realized the power of this solution to reduce waste and accelerate research by connecting bench researchers to a steady supply of remnant clinical samples.

Justin Barad, MD Co-Founder & CEO

Osso VR

Osso VR is an award winning VR surgical and medical device training platform. The company is made up of practicing clinicians, professional VR developers and medtech industry veterans. We specialize in hyper-realistic, haptic-enhanced, hands-on interactivity and design.

Erik de Heus, CEO

SkinVision

SkinVision is an awareness and tracking solution that supports individuals with the early recognition of melanoma, squamous cell carcinoma, basal cell carcinoma and precancerous actinic keratosis. SkinVision is the first certified skin cancer application globally based on extensive clinical trials in partnership with the university clinic of Ludwig Maximilian University (LMU) in Munich in 2013, published in the JEADV in 2014. The company has built up a customer portfolio of 1,200,000 users globally and a database of 3,5 million pictures of suspicious skin conditions.

Dirk Wagener, GM

Stone Three Healthcare

Cardiovascular disease or CVD is a global problem. Though typically viewed as a “rich-world disease”, it has now migrated to many developing countries. The rising prevalence of CVD, today, calls for cost-effective and intelligent patient-centric healthcare technology that empowers care teams and has a real impact on patients.

Gabriela Fuentes, COO

Transmural Biotech S.L

The value of AI has been accelerating the healthcare space at an increasing rate. In fact, AI-powered medical diagnostics is today driving the critical changes across the care continuum. However, AI technologies are not believed to replace doctors despite its transformative power. “We view AI only as a new medical device that allows doctors to ‘better see’ each case,” says Gabriela Fuentes, COO, Transmural Biotech or TMB. “For instance, doctors with different degrees of training reach different conclusions on a clinical diagnosis. Instead, if they have access to data-driven AI image processing technology to support their decision, objective results can be attained regardless of their training.” Upholding the same principle, TMB develops innovative clinical solutions and services using disruptive technologies based on AI.

Nersi Nazari, CEO

Vitalconnect

VitalConnect provides physicians, nurses and patients with an extraordinary advancement in healthcare. Never before has so much continuous monitoring of vital signs been possible in a single, small—yet powerful—device. By consolidating eight critical vital signs into one wireless biosensor,VitalPatch enables a new view into healthcare, but more importantly it connects all interested parties in a patient’s recovery with each other.